Q-omics provides the consensus-scored RPL17P25 profile across patient tissues and cancer cell-line models. RPL17P25 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, RPL17P25 is differentially expressed in 7, with the highest sampling consensus in UCEC. Additionally, RPL17P25 RNA expression shows 14,431 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight UVM, UCEC, and HNSC as cancer lineages where RPL17P25 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL17P25 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL17P25 survival associations across molecular data types. RPL17P25 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL17P25 RNA expression–survival associations across cancer types. High RPL17P25 expression shows unfavorable associations in UVM, MESO, LUAD and ACC, but favorable associations in LUSC and LAML. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for RPL17P25 RNA expression.
This table summarizes RPL17P25 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in UCEC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL17P25. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL17P25 shows lower tumor expression in UCEC, BLCA, ESCA and STAD and higher tumor expression in KIRC and COAD. The UCEC box plot shows higher RPL17P25 RNA expression in normal versus tumor tissue (log2 FC = −0.208, t-test p = .010).
This table shows molecular features associated with RPL17P25 in patient tissues and cancer cell lines. In patient samples, RPL17P25 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set.
